Related Experiment Video
Updated: Jun 21, 2026
09:32
A Next-generation Tissue Microarray (ngTMA) Protocol for Biomarker Studies
Published on: September 23, 2014
[Tissue microarray (TMA) validated progression markers in colorectal cancer using antibody microarrays]
Sándor Spisák1, Barnabás Galamb, Barnabás Wichmann
1Semmelweis Egyetem, Altalános Orvostudományi Kar, II. Belgyógyászati Klinika, Budapest. spisak@abc.hu
Orvosi Hetilap
|August 4, 2009
Summary
Researchers identified 67 altered proteins in colorectal cancer, including key markers for apoptosis and cell cycle regulation. A panel of six proteins effectively distinguishes normal, early, and late-stage colorectal cancer.
Area of Science:
- Molecular biology
- Oncology
- Proteomics
Context:
- Colorectal cancer (CRC) development and progression lack defined molecular markers.
- Microarray technology enables simultaneous analysis of numerous biological parameters.
Purpose:
- Identify potential protein biomarkers for CRC development and progression using antibody arrays.
- Validate identified markers on CRC tissue microarrays.
- Determine a diagnostic marker combination at the protein level for CRC.
Summary:
- Analysis of 16 patient samples (10 Dukes B, 6 Dukes D) revealed 67 differentially expressed proteins (p < 0.05) between normal and cancerous colon tissues.
- Altered proteins are involved in critical cellular functions including apoptosis, cell cycle regulation, transcription, DNA replication, transport, and cell adhesion.
- Twelve candidate markers were validated via immunohistochemistry on tissue microarrays, with a subset of six proteins showing high sensitivity and specificity in differentiating CRC stages.
Impact:
- Provides novel protein markers for understanding CRC pathogenesis.
- Establishes a potential diagnostic tool for early and late-stage CRC detection.
- Advances molecular diagnostics in oncology through proteomic analysis.
